MedTrace Logo

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

NCT06818474 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-02-25

No results posted yet for this study

Summary

use of lanadelumab in patients with acquired angioedema

Conditions

  • Angioedema

Interventions

BIOLOGICAL

Lanadelumab 300 mg

no other intervention

Sponsors & Collaborators

  • Bernstein Clinical Research Center

    lead OTHER

Principal Investigators

  • Jonathan Bernstein, MD · 5139314181

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2027-09-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06818474 on ClinicalTrials.gov